Clinical Trials

  • Principal Investigator:

    Jennifer M. Bain, MD, PhD
    A natural history study of hnRNP and other genetic neurodevelopmental disorders.
  • Principal Investigator:

    Richard P. Mayeux, MD, MSc
    The goal of this study is to focus on the genetic influences on Alzheimer's disease (AD) risk. We are looking for families and/or individuals (affected or unaffected) of any ethnic background with a family history of Alzheimer's disease and willing to participate.
  • Principal Investigator:

    Matthew B. Harms, MD
    This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses. This study provides genetic counseling and testing to help participants understand and manage their risk and determine if they want to learn their genetic status. This study will follow unaffected ALS gene mutation carriers on an annual basis to gather essential information that will ultimately help researchers develop novel therapies for the prevention and treatment of ALS. The ALS...
  • Principal Investigator:

    Scott A. Small, MD
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...
  • Principal Investigator:

    Scott A. Small, MD
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...
  • Principal Investigator:

    Patrick J. Lao, PhD
    The purpose of this study is to determine how inflammation is related to changes in the brain that occur during the progression of Alzheimer's disease. If you are eligible for this study, we will ask you to complete 3-4 study visits over the course of about 5 months. Participation includes memory testing, a blood draw, MRI, PET scans, and a lumbar puncture (spinal tap). You will be compensated $750 plus travel costs. After 2 years, we will invite you to return for a follow-up.
  • Principal Investigator:

    Patrick J. Lao, PhD
    The purpose of this study is to determine how inflammation is related to changes in the brain that occur during the progression of Alzheimer's disease. If you are eligible for this study, we will ask you to complete 3-4 study visits over the course of about 5 months. Participation includes memory testing, a blood draw, MRI, PET scans, and a lumbar puncture (spinal tap). You will be compensated $750 plus travel costs. After 2 years, we will invite you to return for a follow-up.
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    The purpose of this study is to Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN). To be in this study you must have type II Diabetes Mellitus, PDPN, must be 18 years of age or older, and be able to stop taking some of your current pain medications including pills, creams, patches, marijuana, cannabidiol (CBD) oil, etc. Acetaminophen (commonly known as Tylenol) is the only allowable pain medication other than the study drug.
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    The purpose of this study is to Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN). To be in this study you must have type II Diabetes Mellitus, PDPN, must be 18 years of age or older, and be able to stop taking some of your current pain medications including pills, creams, patches, marijuana, cannabidiol (CBD) oil, etc. Acetaminophen (commonly known as Tylenol) is the only allowable pain medication other than the study drug.
  • Principal Investigator:

    Adam M. Brickman, PhD
    The purpose of this study is to better understand how vascular health affects your thinking abilities. We hope that these findings will ultimately lead to treatments aimed to reduce cognitive impairment and dementia. We are actively recruiting adults between the ages of 65 and 90 who note some decline in memory or thinking over the past 3 years and who are of African American, Hispanic/Latino, or European ancestry. You will be asked to return to the Columbia University Medical Center every 12 to 18 months for a total of 3 assessments. At each visit, you will be asked to complete a series of...

Pages